Advertisement

Analytical and Bioanalytical Chemistry

, Volume 410, Issue 6, pp 1785–1792 | Cite as

A simple and precise method to detect sterol esterification activity of lecithin/cholesterol acyltransferase by high-performance liquid chromatography

  • Yu Wang
  • Siming Wang
  • Lijiao Zhang
  • Jie Zeng
  • Ruiyue Yang
  • Hongxia Li
  • Yueming Tang
  • Wenxiang Chen
  • Jun Dong
Research Paper

Abstract

The measurement of lecithin: cholesterol acyltransferase (LCAT, EC 2.3.1.43) activity is important in high-density lipoprotein (HDL) metabolism study and cardiovascular disease (CVD) risk assessment. However, current methods suffer from complex design and preparation of exogenous substrate, low reproducibility, and interference of cofactors. In this study, we developed a simple and precise high performance liquid chromatography (HPLC) method for the measurement of LCAT activity. By using 7-dehydrocholesterol (7-DHC) and 1,2-didecanoyl-sn-glycero-3-phosphocholine(10:0PC) as substrates, and an LCAT activating peptide (P642) as activator and emulsifier, the substrate reagent was easily made by vortex. The substrate reagent was mixed with serum samples (50:1, v/v) and incubated at 37 °C for 1 h. After incubation, the lipid was extracted with hexane and ethanol. With a conjugated double bond and ultraviolet absorption, 7-DHC and its esterification product could be separated and analyzed by a single HPLC run without calibration. LCAT activity was a linear function of the serum sample volume and the intra- and total assay coefficients of variation (CV) less than 2.5% were obtained under the standardized conditions. The substrate reagent was stable, and assay result accurately reflected LCAT activity. LCAT activities in 120 healthy subjects were positively correlated with triglyceride (P < 0.05), fractional esterification rate of HDL cholesterol (FERHDL) (P < 0.0001), and negatively correlated with apolipoprotein AI (apoAI) (P < 0.05) and HDL cholesterol (HDL-C) (P < 0.001). These results suggest that this method is sensitive, reproducible, and not greatly influenced by serum components and added substances, and will be a useful tool in the lipid metabolism study and the risk assessment of CVD.

Keywords

High-density lipoprotein Lecithin: cholesterol acyltransferase Enzyme activity Sterol esterification Chromatography Cardiovascular disease 

Abbreviations

CER

Cholesterol esterification rate

CVD

Cardiovascular diseases

FC

Free cholesterol

FERHDL

Fractional esterification rate of HDL cholesterol

HDL

High-density lipoprotein

HDL-C

HDL cholesterol

LCAT

Lecithin/cholesterol acyltransferase

PC

Phosphatidylcholine

P642

LCAT-activating peptide

RCT

Reverse cholesterol transport

7-DHC

7-Dehydrocholesterol

Notes

Acknowledgments

This study was supported by research grants from the National Natural Science Foundation of China (81472035, 81171647, 81501842).

Compliance with ethical standards

This study was reviewed and approved by the Beijing Hospital Ethics Committee. All studied individuals were informed in writing of the intended use of their samples and each provided written consent.

Conflict of interest

No authors declared any potential conflicts of interest. The funding organizations played no role in the design of the study, review and interpretation of data, or preparation or approval of the manuscript.

Supplementary material

216_2017_834_MOESM1_ESM.pdf (610 kb)
ESM 1 (PDF 506 kb).

References

  1. 1.
    Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, et al. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7(5):484–525.CrossRefGoogle Scholar
  2. 2.
    Scarpioni R, Paties C, Bergonzi G. Dramatic atherosclerotic vascular burden in a patient with familial lecithin-cholesterol acyltransferase (LCAT) deficiency. Nephrol Dial Transplant. 2008;23(3):1074. author reply 1074-1075CrossRefGoogle Scholar
  3. 3.
    Kuivenhoven JA, van Voorst tot Voorst EJ, Wiebusch H, Marcovina SM, Funke H, Assmann G, et al. A unique genetic and biochemical presentation of fish-eye disease. J Clin Invest. 1995;96(6):2783–91.CrossRefGoogle Scholar
  4. 4.
    Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99.CrossRefGoogle Scholar
  5. 5.
    Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.CrossRefGoogle Scholar
  6. 6.
    Sethi AA, Sampson M, Warnick R, Muniz N, Vaisman B, Nordestgaard BG, et al. High pre-beta1 HDL concentrations and low lecithin:cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem. 2010;56(7):1128–37.CrossRefGoogle Scholar
  7. 7.
    Dullaart RP, Tietge UJ, Kwakernaak AJ, Dikkeschei BD, Perton F, Tio RA. Alterations in plasma lecithin:cholesterol acyltransferase and myeloperoxidase in acute myocardial infarction: implications for cardiac outcome. Atherosclerosis. 2014;234(1):185–92.CrossRefGoogle Scholar
  8. 8.
    Dullaart RP, Perton F, van der Klauw MM, Hillege HL, Sluiter WJ. High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis. 2010;208(2):537–42.CrossRefGoogle Scholar
  9. 9.
    Dullaart RP, Perton F, Sluiter WJ, de Vries R, van Tol A. Plasma lecithin:cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J Clin Endocrinol Metab. 2008;93(12):4860–6.CrossRefGoogle Scholar
  10. 10.
    Tanaka S, Yasuda T, Ishida T, Fujioka Y, Tsujino T, Miki T, et al. Increased serum cholesterol esterification rates predict coronary heart disease and sudden death in a general population. Arterioscler Thromb Vasc Biol. 2013;33(5):1098–104.CrossRefGoogle Scholar
  11. 11.
    Calabresi L, Baldassarre D, Simonelli S, Gomaraschi M, Amato M, Castelnuovo S, et al. Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk. J Lipid Res. 2011;52(8):1569–74.CrossRefGoogle Scholar
  12. 12.
    Holleboom AG, Kuivenhoven JA, Vergeer M, Hovingh GK, van Miert JN, Wareham NJ, et al. Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study. J Lipid Res. 2010;51(2):416–21.CrossRefGoogle Scholar
  13. 13.
    Marcel YL, Vezina C. A method for the determination of the initial rate of reaction of lecithin:cholesterol acyltransferase in human plasma. Biochim Biophys Acta. 1973;306(3):497–504.CrossRefGoogle Scholar
  14. 14.
    Dobiasova M, Adler L, Ohta T, Frohlich J. Effect of labeling of plasma lipoproteins with [(3)H]cholesterol on values of esterification rate of cholesterol in apolipoprotein B-depleted plasma. J Lipid Res. 2000;41(8):1356–7.Google Scholar
  15. 15.
    Dong J, Yu S, Yang R, Li H, Guo H, Zhao H, et al. A simple and precise method for direct measurement of fractional esterification rate of high density lipoprotein cholesterol by high performance liquid chromatography. Clin Chem Lab Med. 2014;52(4):557–64.CrossRefGoogle Scholar
  16. 16.
    Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem. 2003;49(11):1873–80.CrossRefGoogle Scholar
  17. 17.
    Chen CH, Albers JJ. Characterization of proteoliposomes containing apoprotein A-I: a new substrate for the measurement of lecithin:cholesterol acyltransferase activity. J Lipid Res. 1982;23(5):680–91.Google Scholar
  18. 18.
    Manabe M, Abe T, Nozawa M, Maki A, Hirata M, Itakura H. New substrate for determination of serum lecithin:cholesterol acyltransferase. J Lipid Res. 1987;28(10):1206–15.Google Scholar
  19. 19.
    Vaisman BL, Remaley AT. Measurement of lecithin-cholesterol acyltransferase activity with the use of a peptide-proteoliposome substrate. Methods Mol Biol. 2013;1027:343–52.CrossRefGoogle Scholar
  20. 20.
    Fielding CJ, Shore VG, Fielding PE. Lecithin:cholesterol acyltransferase: effects of substrate composition upon enzyme activity. Biochim Biophys Acta. 1972;270(4):513–8.CrossRefGoogle Scholar
  21. 21.
    Homan R, Esmaeil N, Mendelsohn L, Kato GJ. A fluorescence method to detect and quantitate sterol esterification by lecithin:cholesterol acyltransferase. Anal Biochem. 2013;441(1):80–6.CrossRefGoogle Scholar
  22. 22.
    Piran U, Nishida T. Utilization of various sterols by lecithin-cholesterol acyltransferase as acyl acceptors. Lipids. 1979;14(5):478–82.CrossRefGoogle Scholar
  23. 23.
    Bartholome M, Niedmann D, Wieland H, Seidel D. An optimized method for measuring lecithin:cholesterol acyltransferase activity, independent of the concentration and quality of the physiological substrate. Biochim Biophys Acta. 1981;664(2):327–34.CrossRefGoogle Scholar
  24. 24.
    Dobiasova M, Frohlich J, Sedova M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011;52(3):566–71.CrossRefGoogle Scholar
  25. 25.
    Liu J, Yang R, Zhou M, Mao W, Li H, Zhao H, et al. Fractional esterification rate of cholesterol in high-density lipoprotein associates with risk of coronary heart disease. Lipids Health Dis. 2017;16(1):162.CrossRefGoogle Scholar
  26. 26.
    Albers JJ, Chen CH, Adolphson JL. Lecithin:cholesterol acyltransferase (LCAT) mass; its relationship to LCAT activity and cholesterol esterification rate. J Lipid Res. 1981;22(8):1206–13.Google Scholar
  27. 27.
    Tani S, Takahashi A, Nagao K, Hirayama A. Association of lecithin–cholesterol acyltransferase activity measured as a serum cholesterol esterification rate and low-density lipoprotein heterogeneity with cardiovascular risk: a cross-sectional study. Heart Vessel. 2015;31(6):831–40.CrossRefGoogle Scholar
  28. 28.
    Hovig T, Gjone E. Familial plasma lecithin:cholesterol acyltransferase (LCAT) deficiency. Ultrastructural aspects of a new syndrome with particular reference to lesions in the kidneys and the spleen. Acta Pathol Microbiol Scand A Pathol. 1973;81(5):681–97.Google Scholar
  29. 29.
    Wells IC, Peitzmeier G, Vincent JK. Lecithin:cholesterol acyltransferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol. 1986;45(3):303–10.CrossRefGoogle Scholar
  30. 30.
    Kobori K, Saito K, Ito S, Kotani K, Manabe M, Kanno T. A new enzyme-linked immunosorbent assay with two monoclonal antibodies to specific epitopes measures human lecithin-cholesterol acyltransferase. J Lipid Res. 2002;43(2):325–34.Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Yu Wang
    • 1
    • 2
  • Siming Wang
    • 2
  • Lijiao Zhang
    • 2
  • Jie Zeng
    • 3
  • Ruiyue Yang
    • 2
  • Hongxia Li
    • 2
  • Yueming Tang
    • 1
  • Wenxiang Chen
    • 3
  • Jun Dong
    • 1
    • 2
  1. 1.Peking University Fifth School of Clinical Medicine, Beijing HospitalBeijingChina
  2. 2.The MOH Key Laboratory of Geriatrics, Beijing Hospital, National Center of GerontologyBeijingChina
  3. 3.Beijing Hospital and National Center for Clinical LaboratoriesBeijingChina

Personalised recommendations